



# Microvascular dysfunction in COVID-19: the MYSTIC study

Alexandros Rovas<sup>1</sup> · Irina Osiaevi<sup>1</sup> · Konrad Buscher<sup>1</sup> · Jan Sackarnd<sup>2</sup> · Phil-Robin Tepas<sup>3</sup> · Manfred Fobker<sup>4</sup> · Joachim Kühn<sup>5</sup> · Stephan Braune<sup>6</sup> · Ulrich Göbel<sup>7</sup> · Gerold Thölking<sup>1,8</sup> · Andreas Gröschel<sup>9</sup> · Hermann Pavenstädt<sup>1</sup> · Hans Vink<sup>10</sup> · Philipp Kümpers<sup>1</sup>

Received: 16 September 2020 / Accepted: 28 September 2020 / Published online: 14 October 2020  
© The Author(s) 2020

## Abstract

**Rationale** Pre-clinical and autopsy studies have fueled the hypothesis that a dysregulated vascular endothelium might play a central role in the pathogenesis of ARDS and multi-organ failure in COVID-19.

**Objectives** To comprehensively characterize and quantify microvascular alterations in patients with COVID-19.

**Methods** Hospitalized adult patients with moderate-to-severe or critical COVID-19 ( $n = 23$ ) were enrolled non-consecutively in this prospective, observational, cross-sectional, multi-center study. Fifteen healthy volunteers served as controls. All participants underwent intravital microscopy by sidestream dark field imaging to quantify vascular density, red blood cell velocity ( $V_{RBC}$ ), and glycocalyx dimensions (perfused boundary region, PBR) in sublingual microvessels. Circulating levels of endothelial and glycocalyx-associated markers were measured by multiplex proximity extension assay and enzyme-linked immunosorbent assay.

**Measurements and main results** COVID-19 patients showed an up to 90% reduction in vascular density, almost exclusively limited to small capillaries (diameter 4–6  $\mu\text{m}$ ), and also significant reductions of  $V_{RBC}$ . Especially, patients on mechanical ventilation showed severe glycocalyx damage as indicated by higher PBR values (i.e., thinner glycocalyx) and increased blood levels of shed glycocalyx constituents. Several markers of endothelial dysfunction were increased and correlated with disease severity in COVID-19. PBR (AUC 0.75,  $p = 0.01$ ), ADAMTS13 (von Willebrand factor-cleaving protease; AUC 0.74,  $p = 0.02$ ), and vascular endothelial growth factor A (VEGF-A; AUC 0.73,  $p = 0.04$ ) showed the best discriminatory ability to predict 60-day in-hospital mortality.

**Conclusions** Our data clearly show severe alterations of the microcirculation and the endothelial glycocalyx in patients with COVID-19. Future therapeutic approaches should consider the importance of systemic vascular involvement in COVID-19.

**Keywords** COVID-19 · Sublingual microscopy · Endothelial glycocalyx · Endotheliopathy · Microcirculation

## Abbreviations

ACE2	Shed ectodomain of angiotensin-converting enzyme 2 receptor	Angpt-1	Angiopoietin-1
ADAMTS13	A disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13	Angpt-2	Angiopoietin-2
AKI	Acute kidney injury	Arb. unit	Arbitrary unit
		ARDS	Acute respiratory distress syndrome
		AUC	Area under the curve
		BMI	Body mass index
		CCI score	Charlson comorbidity index
		COVID-19	Corona virus disease 2019
		CRP	C-reactive protein
		$D_{4-6 \mu\text{m}}$	Capillary density
		eGC	Endothelial glycocalyx
		FDR	False discovery rate
		HA	Hyaluronic acid
		hs-Troponin	High-sensitive troponin
		ICU	Intensive care unit
		IL-6	Interleukin-6
		IMC	Intermediate care ward

Alexandros Rovas and Irina Osiaevi have contributed equally and are both considered first authors.

**Electronic supplementary material** The online version of this article (<https://doi.org/10.1007/s10456-020-09753-7>) contains supplementary material, which is available to authorized users.

✉ Philipp Kümpers  
philipp.kuempers@ukmuenster.de

Extended author information available on the last page of the article

IQR	Interquartile range
MAP	Mean arterial pressure
MV	Mechanical ventilation
PaO <sub>2</sub> /FiO <sub>2</sub> index	The ratio of partial pressure of oxygen in blood (PaO <sub>2</sub> ), in millimeters of mercury, and the fraction of oxygen in the inhaled air (FiO <sub>2</sub> )
PBR	Perfused boundary region
PCT	Procalcitonin
RBC	Red blood cell
RBCW	Red blood cell width
ROC	Receiver operating curve
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
SDF	Sidestream dark field
SIC score	Sepsis-induced coagulopathy score
SOFA score	Sequential Organ Failure Assessment score
Soluble Flt-1	Soluble Fms-like tyrosine kinase-1
Soluble Tie2	Angiopietin-1 receptor
TF	Tissue factor
TM	Thrombomodulin
TMA	Thrombotic microangiopathy
TNF- $\alpha$	Tumor necrosis factor $\alpha$
VEGF-A	Vascular endothelial growth factor A
VEGF-D	Vascular endothelial growth factor D
V <sub>RBC</sub>	Capillary red blood cell velocity
VWF	von Willebrand factor
UKM	University Hospital Münster
w/	With
w/o	Without

## Introduction

Despite about 26 million infections and nearly 870,000 deaths worldwide (04 September 2020), the pathophysiological pathways responsible for the wide clinical spectrum of COVID-19 remain still incompletely understood [1, 2]. Although the natural course of the disease in individuals infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is often mild, up to 15% of patients need hospital treatment [3]. These patients not only develop pulmonary disease, eventually culminating in acute respiratory distress syndrome (ARDS), but also display a myriad of extrapulmonary symptoms, including acute kidney injury (AKI), acute cardiac injury, coagulopathy, thromboembolic complications, including stroke and pulmonary embolism, and circulatory shock [2, 4]. Elegant *in vitro* experiments and *autopsy* studies revealed that SARS-CoV-2 binds to amply expressed angiotensin-converting enzyme 2 (ACE2) receptor and infests directly the endothelial cells [5, 6]. This finding has fueled the hypothesis that COVID-19 is actually

a vascular illness and that systemic leakiness and adhesiveness of the dysregulated vascular endothelium might play a central role in the pathogenesis of ARDS and multi-organ failure [7–9].

Long underestimated as a passive lining of blood vessels, the vascular endothelium is now perceived as an independent organ system that is centrally involved in the control of thrombosis and thrombolysis, platelet and leucocyte interaction with the vessel wall, regulation of vascular tone, and the passage of fluids [10]. More recent data show that the endothelium is shielded against pathogenic insults by the endothelial glycocalyx (eGC)—a gel-like, negatively charged, up to 3- $\mu$ m-thick layer consisting of highly sulfated glycosaminoglycans and proteoglycans. In bacterial sepsis, damage of the eGC plays a causative role in leukocyte recruitment, hyperpermeability, and the development of end-organ damage, especially ARDS and AKI [10].

Therefore, the aim of this prospective, cross-sectional, multi-center study was to characterize and quantify endothelial alterations in patients with moderate-to-severe or critical illness due to COVID-19. Besides multiplex analysis of circulating endothelial and glycocalyx-associated markers, we used a novel state-of-the-art image acquisition and analysis approach to detect *in vivo* even subtle alterations of the sublingual microcirculation.

## Materials and methods

### Study population and study design

This multi-center, prospective, observational, cross-sectional study took place from May to June 2020 in the intensive care units (ICU) and intermediate care wards (IMC) of the University Hospital Münster (UKM) and three local teaching hospitals (St. Franziskus-Hospital Münster, Clemens Hospital Münster, UKM-Marienhospital Steinfurt). The study was approved by the competent ethics committee (amendments of 2016-073-f-S) and was performed in accordance with the Declaration of Helsinki.

After written informed consent was obtained from the patients or their legal representatives, adult hospitalized patients with moderate/severe (IMC) or critical (ICU) COVID-19 disease were enrolled in a non-consecutive fashion by the same team of investigators. Fifteen apparently healthy volunteers served as controls.

Demographic, laboratory, and physiological variables and scores were documented for each participant immediately before the assessment of the sublingual microvasculature. Sublingual video microscopy was performed by an experienced physician. Plasma samples from patients ( $n = 23$ ) and controls ( $n = 11$ ) were obtained, immediately centrifuged at 4 °C with 4000 $\times$ g for 10 min, and stored at

– 80 °C for further analysis of the endothelial and inflammation components.

### Follow-up and outcome definition

Patients' clinical course was prospectively followed up for a period of 60 days after study inclusion or until hospital discharge. In-hospital mortality was the primary outcome studied. Secondary outcomes studied were (a) development of moderate/severe ARDS during hospital stay, defined as a ratio of arterial oxygen partial pressure (PaO<sub>2</sub> in mmHg) to fractional inspired oxygen (FiO<sub>2</sub> expressed as a fraction)  $\leq 200$  mmHg based on the Berlin criteria [11], and (b) presence of thrombotic events, defined as the presence or development of clinically relevant vascular thrombotic or thromboembolic events.

### In vivo assessment of the sublingual microcirculation and glycocalyx dimensions

Details of the technique used to assess the sublingual microcirculation are provided in the online data supplement. Briefly, a sidestream dark field (SDF) camera (CapiScope HVCS, KK Technology, Honiton, UK) coupled to the GlycoCheck™ software (Microvascular Health Solutions Inc., Alpine, UT, USA) was used to visualize the sublingual microvasculature on the bedside. The software calculates the dynamic lateral movement of RBCs into the permeable part of the eGC layer, expressed as the perfused boundary region (PBR, in  $\mu\text{m}$ ) — an inverse parameter of endothelial glycocalyx dimensions.

Vascular perfused density ( $\text{mm}/\text{mm}^2$ ) can be determined from the number of vascular segments containing RBCs multiplied by vascular segment length (10  $\mu\text{m}$ ). All detected RBC-containing vascular segments with a diameter between 4 and 25  $\mu\text{m}$  were automatically counted in the video recordings of each subject. Perfused vascular density (hereafter vascular density) was normalized to tissue surface area. The pooled density of capillaries between 4 and 6  $\mu\text{m}$  is defined as *capillary density* ( $D_{4-6\mu\text{m}}$ ).

RBC velocities ( $\mu\text{m}/\text{s}$ ) are expressed in individual vessel segments by cross correlation of longitudinal RBC intensity profiles between consecutive frames of recorded videos and are calculated by dividing RBC displacement by the time between video frames. A correlation coefficient of  $\geq 0.85$  was required to allow accurate estimates of longitudinal RBC displacement. The median RBC velocities of the capillaries with a diameter between 4 and 7  $\mu\text{m}$  were defined as capillary RBC velocity ( $V_{\text{RBC}}$ ).

To avoid contamination of the equipment, laptop, cables, and camera were covered with a transparent disposable plastic wrap. Between measurements, the whole equipment was cleaned twice with antiviral wipes appropriate for medical

products. The physician conducting the video microscopy was equipped with a full personal protective equipment (PPE), as instructed, and was approved by our local department of hygiene.

### Circulating markers of endothelial dysfunction, inflammation, and injury

The endothelial markers analyzed in this study were selected a priori because of their pathophysiological relevance for the integrity of the vascular barrier and/or COVID-19 pathophysiology, respectively. Circulating levels of endothelial growth factor A and D (VEGF-A, VEGF-D), angiotensin-1 (Angpt-1), von Willebrand factor-cleaving protease (ADAMTS13), soluble angiotensin-1 receptor (soluble TIE2), tissue factor (TF), soluble thrombomodulin (TM), shed ectodomain of angiotensin-converting enzyme 2 receptor (ACE2), and tumor necrosis factor-alpha (TNF- $\alpha$ ) were measured in plasma by a customized multiplex proximity extension assay (Olink, Utrecht, the Netherlands). These protein concentrations are presented in arbitrary units (arb. units) on a linear normalized scale.

Plasma levels of glycocalyx-associated proteins syndecan-1 (Diacalone, Besançon, France) and hyaluronic acid (HA; Echelon Biosciences Inc., Salt Lake City, UT, USA), as well as angiotensin-2 (Angpt-2; R&D Systems, Minneapolis, USA) were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions. Soluble Fms-like tyrosine kinase-1 (sFlt-1), high-sensitive troponin (hs-Troponin), D-dimer, and interleukin-6 (IL-6) were measured as part of clinical routine in the center for laboratory medicine (UKM, Münster, Germany). All measurements were performed in a blinded fashion.

### Statistical analysis

Data are presented as absolute numbers, percentages, and medians with corresponding 25th and 75th percentiles (interquartile range; IQR), as appropriate. The non-parametric Mann–Whitney *U* test and the chi-square test were used to compare parameters between groups. To correct for multiple testing in comparisons of microcirculation parameters per diameter class, we used the false discovery rate (FDR) approach of Benjamini, Krieger, and Yekutieli, setting a *q*-value  $< 0.05$  as significant. Spearman rank correlation coefficient (*r*<sub>s</sub>) was used to assess correlations between variables. Receiver–operator characteristic (ROC) analysis was used to assess the area under the curve (AUC) and identify optimal cut-off values. The distribution of the time-to-event variables was estimated using the Kaplan–Meier method with log-rank testing. All the tests used were two-sided, and statistical significance was set at  $p < 0.05$ . SPSS version 26

(IBM Corporation, Armonk, NY, USA) and GraphPad Prism version 8.4.3 (GraphPad Prism Software Inc., San Diego, CA, USA) were used for statistical analyses and preparation of figures.

## Results

The COVID-19 cohort consisted of 23 adult patients with median (IQR) age of 62 (54–75) years. Most of the patients were male ( $n=20$ ; 87%), overweight (BMI: 26.6 kg/m<sup>2</sup> [IQR: 23.4–29.4]), and had a history of arterial hypertension ( $n=15$ ; 65%). Fourteen patients (61%) were mechanically ventilated at study inclusion. The clinical and demographic characteristics of COVID-19 patients are shown in Table 1. Fifteen apparently healthy controls (age [IQR]: 35 [28–66]; 53% female) determined the normal range of the different markers.

### Vascular density, RBC velocity, and glycocalyx damage

Sublingual video microscopy showed severe alterations of the microvasculature in COVID-19 patients. First, we compared vascular density between healthy controls and COVID-19 patients in a diameter-class-wise fashion (Fig. 1a, b). This approach revealed a tremendous decrease in vascular density in the diameter classes 4–10  $\mu\text{m}$  in mechanically ventilated patients compared to controls. A similar, albeit less pronounced, pattern was observed in patients without need for mechanical ventilation (MV) (Fig. 1a, b). Interestingly, the capillary density loss ( $D_{4-6\mu\text{m}}$ ) in COVID-19 patients correlated with D-dimer levels ( $r_s = -0.43$ ,  $p=0.04$ , Figure E1: Online Supplement). Density of microvessels  $> 10 \mu\text{m}$  was not different between the three groups, indicating that the small capillaries are primarily affected. Moreover,  $V_{\text{RBC}}$  in these capillaries was significantly lower in mechanically ventilated patients compared to healthy individuals (81.7  $\mu\text{m/s}$  [74.3–91.9] vs. 106.4  $\mu\text{m/s}$  [95.5–121.0],  $p=0.004$ ). COVID-19 patients without need for MV showed normal  $V_{\text{RBC}}$  values (106.4  $\mu\text{m/s}$  [95.5–121.1] vs. 99.4  $\mu\text{m/s}$  [86.8–118.0],  $p=0.29$ ) (Fig. 1c).

Next, we analyzed the PBR which has been identified as a robust and reliable estimate of glycocalyx damage [12–14]. COVID-19 patients on MV showed significantly higher PBR values (i.e., thinner glycocalyx layer) compared to non-ventilated patients (2.44  $\mu\text{m}$  [2.28–2.55] vs. 2.16  $\mu\text{m}$  [2.01–2.24],  $p=0.002$ ) and controls (2.44  $\mu\text{m}$  [2.28–2.55] vs. 2.24 [2.12–2.33],  $p=0.008$ ), respectively. This finding was corroborated by highly elevated plasma levels of HA and syndecan-1, circulating markers of glycocalyx shedding, which markedly increased with need for MV in COVID-19 patients (Fig. 1d–f). PBR values and syndecan-1 concentrations

correlated moderately not only with each other ( $r_s = 0.50$  [95% CI 0.10–0.76],  $p=0.02$ ), but also with further markers of endothelial dysfunction and injury (Figure E1: Online Supplement). In summary, COVID-19 patients show severe alterations of the microcirculation and the endothelial glycocalyx, which increase with disease severity.

### Circulating markers of endothelial dysfunction, inflammation, and injury

The endothelium-specific Angpt/Tie2 system controls endothelial activation in a non-redundant fashion [15]. While the protective TIE2-agonistic ligand Angpt-1 was not different between the groups, its leakage-inducing antagonist Angpt-2 was significantly increased in COVID-19 patients, especially in those on MV. Soluble TIE2, generated by proteolytic cleavage and release of the ectodomain from full-length receptor located at the cell surface [16], increased in COVID-19 patients (Table 1; Fig. 2a–c).

The vasodilating and permeability factor VEGF-A and its endogenous inhibitor sFlt-1, a truncated and circulating form of the VEGF-A receptor Flt-1, were markedly increased in COVID-19 patients and correlated with disease severity. VEGF-D, which promotes angiogenesis and lymphangiogenesis [17], was lower in COVID-19 patients on MV compared to healthy controls and patients without need for MV (Table 1; Fig. 2d–f).

Levels of ADAMTS13, an antithrombotic metalloprotease which cleaves highly adhesive large von Willebrand factor (VWF) multimers after their release from activated endothelium [18], decreased significantly with increasing COVID-19 severity (Fig. 2g). Circulating fragments of TM, an endothelial injury marker, were markedly increased in COVID-19 patients and correlated with disease severity (Fig. 2h). Levels of the shed ectodomain of ACE2, the main host cell receptor of SARS-CoV-2, correlated with disease activity and increased approximately tenfold in COVID-19 patients on MV (Fig. 2i).

Among routine markers of inflammation, PCT and TNF- $\alpha$ , but not CRP, IL-6 or ferritin, were higher in COVID-19 patients on MV compared to those not on MV (Table 1).

Figure E1 (online supplement) shows a correlation matrix including  $D_{4-6\mu\text{m}}$ ,  $V_{\text{RBC}}$ , glycocalyx and endothelial-associated markers, and inflammatory cytokines. Of note, markers of glycocalyx damage, namely PBR and syndecan-1, correlated positively with D-Dimer levels (PBR:  $r_s = 0.56$ ,  $p < 0.01$ ; syndecan-1:  $r_s = 0.56$ ;  $p < 0.01$ ), ACE2 (PBR:  $r_s = 0.46$ ,  $p < 0.05$ ; syndecan-1:  $r_s = 0.59$ ;  $p < 0.01$ ), and inversely with ADAMTS13 antigen levels (PBR:  $r_s = -0.52$ ,  $p < 0.05$ ; syndecan-1:  $r_s = -0.64$ ,  $p < 0.01$ ).  $D_{4-6\mu\text{m}}$  correlated inversely with D-dimer ( $r_s = -0.43$ ,  $p < 0.05$ ) and ACE2 ( $r_s = -0.46$ ,  $p < 0.05$ ) antigen levels. ADAMTS13 showed moderate

**Table 1** Baseline characteristics of COVID-19 patients stratified for mechanical ventilation

Variable	All patients	w/o Mechanical ventilation	w/ Mechanical ventilation	<i>p</i> value <sup>#</sup>
Number of participants ( <i>n</i> ; %)	23	9 (39.1)	14 (60.9)	–
Female sex ( <i>n</i> ; %)	3 (13)	2 (22)	1 (7)	0.30
Age (years, median (IQR))	62 (54–75)	64 (53–77)	61 (55–67)	0.52
BMI (kg/m <sup>2</sup> , median (IQR))	26.6 (23.4–29.4)	24.3 (22.9–27.9)	27.5 (24.1–32.6)	0.11
Positive nasopharyngeal swab ( <i>n</i> ; %)	22 (96.7)	9 (100)	13 (92.9)*	> 0.99
Viraemia at study inclusion ( <i>n</i> ; %)	2 (8.7)	0 (0)	2 (14.3)	0.50
Days from hospital admission (median (IQR))	7 (1–17)	2 (0.5–21.5)	10 (2.5–18.3)	0.48
ICU at study inclusion ( <i>n</i> ; %)	16 (69.5)	2 (22.2)	14 (100)	0.0001
SOFA score (pts, median (IQR))	6 (2–13)	2 (0–4)	11 (6–16)	< 0.0001
SOFA respiratory (pts, median (IQR))	2 (1–3)	0 (0–2.5)	2.5 (2–3)	0.02
PaO <sub>2</sub> /FiO <sub>2</sub> ratio (median (IQR))	222.50 (164.17–339.29)	342.85 (196.32–502.38)	194.88 (145.76–234.0)	0.02
MAP (mmHg, median (IQR))	78.0 (68.7–89.7)	85.3 (77.3–96.5)	73.2 (64.4–85.7)	0.01
Vasopressors ( <i>n</i> ; %)	6 (26.1)	1 (11.1)	5 (35.7)	0.34
Norepinephrine Dose (µg/kg/min, median (IQR))	0 (0–0.03)	0	0 (0.0–0.5)	0.34
Acute dialysis ( <i>n</i> ; %)	7 (30.4)	0	7 (50)	0.02
60-days in-hospital mortality ( <i>n</i> ; %)	6 (26.1)	1 (11.1)	5 (35.7)	0.34
CCI score (pts, median (IQR))	1 (0–3)	1 (0–2)	0 (0–3.25)	0.73
Comorbidities ( <i>n</i> ; %)				
Arterial hypertension	15 (65.2)	4 (44.4)	11 (78.6)	0.18
Chronic respiratory disease	4 (17.4)	2 (22.2)	2 (14.2)	> 0.99
Congestive heart failure	6 (26.1)	2 (22.2)	4 (28.6)	> 0.99
Rheumatologic disease	4 (17.4)	2 (22.2)	2 (14.2)	> 0.99
Malignancy	5 (21.7)	3 (33.3)	2 (14.3)	0.34
Diabetes mellitus	0	0	0	–
Sublingual microscopy (median (IQR))				
PBR (µm)	2.30 (2.10–2.51)	2.16 (2.01–2.24)	2.44 (2.28–2.55)	0.002
<i>D</i> <sub>4–6 µm</sub> (mm/mm <sup>2</sup> )	24.92 (14.07–52.19)	33.63 (18.22–66.08)	20.80 (11.46–46.79)	0.11
<i>V</i> <sub>RBC</sub> (µm/s)	90.0 (79.9–106.8)	106.4 (95.5–121.0)	81.7 (74.3–91.9)	0.004
Endothelial markers (median (IQR))				
Syndecan-1 (ng/ml)	163.6 (33.5–246.5)	29.9 (22.8–82.4)	239.0 (162.8–251.5)	< 0.0001
Hyaluronic acid (ng/ml)	234.2 (139.8–487.6)	139.9 (113.9–393.9)	240.6 (177.8–723.7)	0.20
Angpt-1 (arb. unit)	122.1 (53.7–183.3)	141.5 (105.0–231.5)	95.7 (40.5–172.4)	0.16
Angpt-2 (ng/ml)	5.5 (3.9–6.6)	4.2 (2.3–5.5)	6.4 (5.0–6.7)	0.06
Soluble Tie2 (arb. unit)	122.0 (98.4–142.2)	104.9 (94.9–135.1)	135.0 (101.1–156.3)	0.16
VEGF-A (arb. unit)	2659.6 (2342.1–4430.5)	2442.6 (1717.2–2660.7)	4067.2 (2584.4–4883.3)	0.005
VEGF-D (arb. unit)	107.4 (80.8–141.3)	140.3 (102.2–147.6)	91.8 (62.3–130.3)	0.051
sFLT-1 (pg/ml)	144.0 (86.1–575.0)	86.1 (71.3–116.5)	471.5 (131.7–672.3)	0.003
ADAMTS13 (arb. unit)	19.0 (16.9–20.7)	20.2 (19.9–24.3)	17.3 (14.7–18.8)	0.001
ACE2 (arb. unit)	27.6 (10.4–41.6)	10.6 (6.4–26.7)	34.1 (23.5–51.8)	0.007
Soluble thrombomodulin (arb. Unit)	685.2 (536.3–909.1)	537.3 (416.0–649.3)	857.1 (646.6–1036.6)	0.004
Tissue factor (arb. Unit)	53.8 (41.0–68.4)	50.85 (30.4–63.4)	59.0 (46.5–69.9)	0.21
D-Dimers (mg/l)	2.52 (1.70–6.04)	1.70 (0.72–2.31)	4.83 (2.90–10.30)	0.001
Inflammatory markers (median (IQR))				
CRP (mg/dl)	12.2 (4.5–21.9)	10.3 (0.9–16.5)	14.2 (11.1–28.0)	0.06
IL-6 (pg/ml)	62.0 (25.0–131.0)	30.0 (9.5–154.0)	69.0 (48.5–154.3)	0.14
Ferritin (µg/l)	1085 (468–1499)	712 (301–972)	1244 (582–2079)	0.12

**Table 1** (continued)


Variable	All patients	w/o Mechanical ventilation	w/ Mechanical ventilation	<i>p</i> value <sup>#</sup>
PCT (ng/ml)	0.64 (0.13–3.16)	0.13 (0.11–0.43)	2.10 (0.40–5.60)	0.006
TNF- $\alpha$ (arb. unit)	8.6 (6.1–10.8)	6.9 (4.8–7.8)	10.3 (8.2–13.3)	0.007
hs-Troponin (ng/l)	76.7 (27.2–198.0)	28.8 (10.5–65.4)	121.0 (36.6–251.0)	0.06

<sup>#</sup>*p*-values were calculated between the two COVID-19 groups (with and without mechanical ventilation)

\*One patient had negative nasopharyngeal swab, but typical signs, symptoms, and radiological findings on the chest computed tomography (CT) at study inclusion

Abbreviations:

*ACE2* shed ectodomain of angiotensin-converting enzyme 2 receptor, *ADAMTS13* a disintegrin and metalloprotease with thrombospondin type 1 motif member 13, *Angpt-1* Angiopoietin-1, *Angpt-2* Angiopoietin-2, *Arb. unit* Arbitrary unit, *BMI* Body mass index, *CCI score* Charlson Comorbidity Index, *CRP* C-reactive protein, *hs-Troponin* high-sensitive Troponin, *ICU* Intensive care unit, *IL-6* Interleukin-6, *IQR* interquartile range, *MAP* Mean arterial pressure, *PBR* Perfused boundary region, *PCT* Procalcitonin, *RBC* Red blood cell, *SOFA score* Sequential Organ Failure Assessment score, *Soluble Flt-1* Soluble Fms-like tyrosine kinase-1, *Soluble Tie2* Angiopoietin-1 receptor, *TNF- $\alpha$*  Tumor necrosis factor  $\alpha$ , *VEGF-A* Vascular endothelial growth factor A, *VEGF-D* Vascular endothelial growth factor D, *w/* with, *w/o* without



**Fig. 1** Endothelial glycocalyx dimensions in vivo and in vitro and capillary density in COVID-19 patients with (w/) and without (w/o) mechanical ventilation (MV) and healthy controls. **a** Median and IQR values of vascular density of healthy controls and COVID-19 patients based on the diameter class from 4 to 25  $\mu\text{m}$ . **b** Bar charts showing the percentage of loss of vascular density in COVID-19 patients with (red) and without (orange) mechanical ventilation com-


pared to healthy controls (diameter class from 4 to 10  $\mu\text{m}$ ). \* $q < 0.05$ , \*\* $q < 0.01$ , \*\*\* $q < 0.001$  Boxplots of **c** of capillary  $V_{\text{RBC}}$ , **d** PBR values, and endothelial glycocalyx constituents **e** syndecan-1 and **f** hyaluronic acid of healthy controls (green) and COVID-19 patients with (red) or without (orange) mechanical ventilation (MV) \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$

to strong inverse association with *Angpt-2* ( $r_s = -0.47$ ,  $p < 0.05$ ), *ACE2* ( $r_s = -0.57$ ,  $p < 0.01$ ), *TM* ( $r_s = -0.64$ ,  $p < 0.01$ ), *D-Dimers* ( $r_s = -0.52$ ,  $p < 0.05$ ), and *VEGF-A* ( $r_s = -0.85$ ,  $p < 0.001$ ).

In summary, our data show a plausible but complex pattern of endothelial dysfunction and damage, in which counter-regulatory mechanisms seem to be operative.

### Association of endothelial dysfunction with clinical parameters and outcome

Table E1 (Online Supplement) shows correlations of selected endothelial parameters with metric clinical variables, such as  $\text{PaO}_2/\text{FiO}_2$  index, Sequential organ failure assessment (SOFA) score, Sepsis-induced coagulopathy




**Fig. 2** Comparisons of a priori selected markers of endothelial dysfunction in COVID-19 patients with and without mechanical ventilation and healthy controls. Boxplots of **a** angiopoietin-1, **b** angiopoietin-2, **c** soluble TIE2, **d** VEGF-A, **e** sFLT-1, **f** VEGF-

**D**, **g** ADAMTS13, **h** soluble thrombomodulin, and **i** ACE2 between healthy controls and COVID-19 patients with (red) and without (orange) mechanical ventilation (MV)

(SIC) score, hs-troponin, and hemodynamics. The performance of endothelial markers to predict clinical outcomes was evaluated using ROC analysis (Table E2 – online supplement). The AUC of ADAMTS13 and syndecan-1 was 0.91 ( $p < 0.0001$ ) while ACE2, D-Dimer, PBR, and VEGF-A showed AUCs  $\geq 0.85$  ( $p < 0.0001$ ) in predicting development of moderate-to-severe ARDS during hospital stay. D-Dimers showed the highest AUC for association of thrombotic events (AUC 0.80,  $p = 0.001$ ), followed by markers of glycocalyx damage, PBR (AUC 0.78,  $p = 0.02$ ), and syndecan-1 (AUC 0.76,  $p = 0.02$ ).

Regarding in-hospital 60-day mortality, PBR (AUC 0.75,  $p = 0.01$ ), ADAMTS13 (AUC 0.74,  $p = 0.02$ ), and VEGF-A (AUC 0.73,  $p = 0.04$ ) showed the best discriminatory ability. ROC-derived cut-off values of these markers were used to divide the COVID-19 cohort into two groups of high and low values, respectively. As shown by Kaplan–Meier curves, high PBR values ( $p = 0.045$ ) and reduced ADAMTS13 antigen levels ( $p = 0.047$ ) were associated with mortality (Fig. 3).



**Fig. 3** Survival probability of COVID-19 patients according to different endothelial markers. Kaplan–Meier curves with 95% CIs showing survival probability of COVID-19 patients with **a** low/high PBR, **b**

low/high ADAMTS13, and **c** low/high VEGF-A. #ADAMTS13 of one patient could not be measured due to technical reasons

## Discussion

Our comprehensive analysis approach, comprising functional and biomarker data clearly shows severe alterations of the microcirculation and the endothelial glycocalyx in patients with COVID-19. Several of those markers were closely related to disease severity and predicted ARDS development. Of note, sublingual glycocalyx thickness and circulating ADAMTS13 and VEGF-A levels, but not initially proposed (inflammatory) markers such as ferritin, CRP, IL-6 or hs-troponin, predicted 60-day in-hospital mortality. Thus, our data provide further evidence for the importance of systemic vascular involvement in COVID-19.

An unspecified, small reduction in total and perfused vascular density in sublingual microvessels of ventilated COVID-19 patients has been recently reported [19, 20]. However, neither outcome nor endothelial or glycocalyx markers have been assessed in these studies. Our detailed per-diameter analysis shows for the first time the exact localization (i.e., true capillaries,  $D_{4-6\mu m}$ ) and incredible extent of capillary dropout (>60%) in mechanically

ventilated COVID-19 patients. Capillary impairment ( $V_{RBC}$  and  $D_{4-6\mu m}$ ) correlated with SOFA and SIC score as well as oxygenation index, indicating that sublingual capillaries are, at least in part, representative of the pulmonary ones. Capillary clogging by fibrinous microthrombi, which has been shown by autopsy studies in lungs from COVID-19 patients [5, 21], is thus the putative histopathological correlate of capillary rarefaction in sublingual capillaries as well. Consistent with this notion, D-dimers levels were closely associated with microcirculatory alterations in our and the abovementioned studies [19, 20].

Local formation of microthrombi and subsequent capillary clogging requires a switch of the endothelial phenotype from quiescence to a pro-adhesive, pro-inflammatory activation state. Interestingly, this process is non-redundantly controlled by Tie2, a receptor that is highly enriched in the endothelium and actively signals vascular quiescence [22]. Under physiological conditions, Tie2 is tonically activated by Angpt-1, a vasculoprotective protein secreted by periendothelial cells and platelets [23]. In human sepsis, its intrinsic antagonist called Angpt-2 is rapidly released from



activated endothelium, competitively inhibits Tie2 and predicts mortality as a biomarker [15, 24, 25]. Elegant translation work by Higgins et al. showed that Angpt-2-driven Tie2 deactivation is central to microvascular thrombus formation in sepsis [26]. Angpt-2 was already increased in non-ventilated SARS-CoV-2 infected patients, indicating that Angpt-2 may unleash endothelial inflammation in COVID-19 early on. In this regard, Smadja et al. identified an Angpt-2 cut-off of 5.0 ng/ml as best early predictor for ICU admission in 40 consecutive COVID-19 patients admitted to the emergency department [27]. Although Angpt-2 correlated with SOFA and SIC scores, it didn't predict clinical outcomes in our cohort of COVID-19 patients.

Among the VEGF system, VEGF-D [28], and sFLT-1 [29] have been discussed in the pathophysiology of COVID-19. Kong et al. reported a *positive* correlation between VEGF-D: a still not fully understood member of the VEGF family – and disease severity in COVID-19 patients [28]. Surprisingly, we found a clear *negative* correlation between VEGF-D and SOFA score. A reason for this discrepancy could be the cross-sectional design of our study, as VEGF-D levels seem to fluctuate during hospital stay [28]. However, VEGF-A, a strong permeability-inducing factor related to disease severity and survival in sepsis [30], correlated positively with disease severity and ARDS development in our cohort. The bioavailability of elevated VEGF-A, however, is difficult to deduce, since sFlt-1 acts as a scavenger receptor and neutralizes VEGF-A. Under healthy conditions, sFlt-1 binds electrostatically to proteoglycans and is, thus, buffered within the glycocalyx [31]. Not surprisingly, glycocalyx damage coincides with excess sFlt-1 levels in COVID-19 patients.

In a comprehensive study on the hypercoagulability in COVID-19, Goshua et al. found evidence of excessive VWF release, but absence of DIC. Both VWF antigen and soluble thrombomodulin, a specific marker of endothelial cell injury were significantly correlated with mortality [32]. In sepsis, elevated VWF antigen and activity can be accompanied by reductions in the ADAMTS13 metalloproteinase responsible for cleaving ultra-large VWF multimers into smaller VWF forms. Mounting VWF/ADAMTS13 imbalance, culminating in the accumulation of uncleaved VWF molecules has been shown to increase the risk of developing secondary thrombotic microangiopathy in sepsis. In line with this finding, ADAMTS13 antigen correlated inversely with glycocalyx damage and SOFA score and predicted ARDS and 60-day mortality in our study [33]. Evidence of reduced ADAMTS13 activity in the presence of schistocytes (~2–4%) appeared compatible with thrombotic microangiopathy (TMA) secondary to COVID-19 [34].


Although some endothelial markers, such as thrombomodulin, have been already linked to mortality in COVID-19 patients [32], the predictive value of the PBR as an estimate of glycocalyx thickness has not been reported yet.

Interestingly, previous work by our group revealed that damage and refurbishment of the eGC are tightly controlled by Tie2 in human sepsis [12, 35]. Mechanistically, Angpt-2 causes heparanase secretion from distinctive cellular storage pools with consecutive enzymatic degradation of the glycocalyx [35]. A groundbreaking translational study by Schmidt et al. provided compelling evidence that prevention of heparanase-mediated degradation of the pulmonary endothelial glycocalyx—by blocking heparanase via a non-coagulant heparin fragment—is sufficient to eliminate vascular hyperpermeability and ARDS in murine endotoxemia [36]. It is intriguing to speculate that a possible off-target effect of heparin, which appears to improve mortality in COVID-19 patients [37], may be the stabilization or restoration of the endothelial glycocalyx. However, the involvement of heparanase in COVID-19-induced glycocalyx damage has yet to be formally demonstrated and needs further study.

We acknowledge some limitations in our study. First, sublingual video microscopy in COVID-19 patients is challenging due to the increased risk of transmission. We therefore started the measurements only after we had developed a safe hygiene protocol. Given that the number of infections in the City of Münster was very low anyway, we had to conduct the study in a cross-sectional fashion with a limited sample size. Therefore, we cannot exclude that the identified predictors may be less meaningful in early disease stages or outpatients, respectively. Second, this study was neither designed nor powered to test the performance of endothelial or microvascular parameters for outcome prediction. However, our findings are plausible, hypothesis-generating, and clearly deserve validation in larger, prospective studies with serial blood drawings and microscopic measurements. Third, although participating centers regularly exchanged information on the basic treatment strategies, these may have differed in detail and, therefore, could have influenced the results. Lastly, most of the COVID-19 patients were of male sex. Indeed, male individuals are more often infected by SARS-CoV2. Our results are therefore only transferable to the female sex with caution.

## Conclusion and outlook

Our data clearly support that COVID-19 is accompanied by endothelial activation, glycocalyx damage, and severe capillary impairment (Fig. 4). Although our data cannot prove causality, it is very likely that COVID-19 has a distinctive vascular phenotype or even represents a novel vascular multisystemic disease. A precise quantification of endothelial glycocalyx damage could be a new parameter for outcome prediction. Future prediction models and therapeutic approaches should, thus, consider the importance of the vascular endothelium and its glycocalyx in COVID-19.



**Fig. 4** Endothelial, glycocalyx, and microcirculation damage in COVID-19. The image illustrates a simplified overview summarizing the findings of this study

**Acknowledgements** Open Access funding enabled and organized by Projekt DEAL. We would like to acknowledge the support of the Open Access Publication Fund of the University of Münster.

**Author contributions** AR had the initial idea, designed the study, supervised the execution of sublingual video microscopy, analyzed the data, prepared the figures, and drafted the manuscript; IO participated in the design of the study, performed the sublingual video microscopy, carried out blood sampling and measurement, analyzed the data, prepared the figures, and contributed to the manuscript; KB, JS, PRT, JK, SB, UG, GT, AG, and HP contributed to the design of the study, discussed the findings, revised the manuscript, and/or enrolled patients; MF contributed to the laboratory measurements, discussed the findings, and revised the manuscript; HV analyzed the video microscopy data offline, advised on the microcirculation analysis, discussed the findings, and revised the manuscript; PK had the initial idea, supervised the study, recruited and coordinated participating centers, contributed to the analysis and figures, and drafted the manuscript.

**Funding** This work was supported by the fund Innovative Medical Research of the University of Münster Medical School (RO221907, to AR and KB) and by the German Research Foundation (KFO342), to AR and PK (KU2873/3-1). The funding sources of the study had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Data availability** The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

## Compliance with ethical standards

**Conflict of interest** IO, KB, JS, PRT, MF, JK, SB, UG, GT, AG, HP, and PK declare no competing interests. AR holds shares of Novavax, Moderna, and Curevac. HV is Chief Science Officer of GlycoCheck BV, The Netherlands.

**Consent to participate** Patients were enrolled upon after obtaining written informed consent from them or their legal representatives.

**Ethics approval** The study was performed in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the General Medical Council Westfalen-Lippe and the WWU Münster, Germany (file number: amendments of 2016-073-f-S).

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

- Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP (2020) The trinity of COVID-19: immunity, inflammation and intervention. *Nat Rev Immunol* 20(6):363–374. <https://doi.org/10.1038/s41577-020-0311-8>
- Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahluwalia N, Ausiello JC, Wan EY, Freedberg DE, Kirtane AJ, Parikh SA, Maurer MS, Nordvig AS, Accilli D, Bathon JM, Mohan S, Bauer KA, Leon MB, Krumholz HM, Uriel N, Mehra MR, Elkind MSV, Stone GW, Schwartz A, Ho DD, Bilezikian JP, Landry DW (2020) Extrapulmonary manifestations of COVID-19. *Nat Med* 26(7):1017–1032. <https://doi.org/10.1038/s41591-020-0968-3>
- Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. *JAMA*. <https://doi.org/10.1001/jama.2020.2648>
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 395(10223):497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)
- Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H (2020) Endothelial cell infection and endothelitis in COVID-19. *Lancet* 395(10234):1417–1418. [https://doi.org/10.1016/S0140-6736\(20\)30937-5](https://doi.org/10.1016/S0140-6736(20)30937-5)
- Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pohlmann S (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 181(2):271–280 e278. <https://doi.org/10.1016/j.cell.2020.02.052>
- Pons S, Fodil S, Azoulay E, Zafrani L (2020) The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. *Crit Care* 24(1):353. <https://doi.org/10.1186/s13054-020-03062-7>
- Okada H, Yoshida S, Hara A, Ogura S, Tomita H (2020) Vascular endothelial injury exacerbates coronavirus disease 2019: the role of endothelial glycocalyx protection. *Microcirculation*. <https://doi.org/10.1111/micc.12654>
- Teuwen LA, Geldhof V, Pasut A, Carmeliet P (2020) COVID-19: the vasculature unleashed. *Nat Rev Immunol* 20(7):389–391. <https://doi.org/10.1038/s41577-020-0343-0>
- Uchimido R, Schmidt EP, Shapiro NI (2019) The glycocalyx: a novel diagnostic and therapeutic target in sepsis. *Crit Care* 23(1):16. <https://doi.org/10.1186/s13054-018-2292-6>
- Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS (2012) Acute respiratory distress syndrome: the Berlin Definition. *JAMA* 307(23):2526–2533. <https://doi.org/10.1001/jama.2012.5669>
- Drost CC, Rovas A, Kusche-Vihrog K, Van Slyke P, Kim H, Hoang VC, Maynes JT, Wennmann DO, Pavenstadt H, Linke W, Lukasz A, Hesse B, Kumpers P (2019) Tie2 activation promotes protection and reconstitution of the endothelial glycocalyx in human sepsis. *Thromb Haemost* 119(11):1827–1838. <https://doi.org/10.1055/s-0039-1695768>
- Rovas A, Seidel LM, Vink H, Pohlkötter T, Pavenstadt H, Ertmer C, Hessler M, Kumpers P (2019) Association of sublingual microcirculation parameters and endothelial glycocalyx dimensions in resuscitated sepsis. *Crit Care* 23(1):260. <https://doi.org/10.1186/s13054-019-2542-2>
- Rovas A, Lukasz AH, Vink H, Urban M, Sackarnd J, Pavenstadt H, Kumpers P (2018) Bedside analysis of the sublingual microvascular glycocalyx in the emergency room and intensive care unit: the GlycoNurse study. *Scand J Trauma Resusc Emerg Med* 26(1):16. <https://doi.org/10.1186/s13049-018-0483-4>
- Sack KD, Kellum JA, Parikh SM (2020) The angiotensin-tie2 pathway in critical illness. *Crit Care Clin* 36(2):201–216. <https://doi.org/10.1016/j.ccc.2019.12.003>
- Reusch P, Barleon B, Weindel K, Martiny-Baron G, Godde A, Siemeister G, Marme D (2001) Identification of a soluble form of the angiotensin receptor TIE-2 released from endothelial cells and present in human blood. *Angiogenesis* 4(2):123–131. <https://doi.org/10.1023/a:1012226627813>
- Byzova TV (2016) “Fishing” out the real VEGFs. *Blood* 128(19):2283–2284. <https://doi.org/10.1182/blood-2016-09-737023>
- Levy GG, Motto DG, Ginsburg D (2005) ADAMTS13 turns 3. *Blood* 106(1):11–17. <https://doi.org/10.1182/blood-2004-10-4097>
- Carsetti A, Damiani E, Casarotta E, Scorcella C, Domizi R, Montomoli J, Gasparri F, Gabbanelli V, Pantanetti S, Carozza R, Adrario E, Donati A (2020) Sublingual microcirculation in patients with SARS-CoV-2 undergoing veno-venous extracorporeal membrane oxygenation. *Microvasc Res*. <https://doi.org/10.1016/j.mvr.2020.104064>
- Damiani E, Carsetti A, Casarotta E, Scorcella C, Domizi R, Adrario E, Donati A (2020) Microvascular alterations in patients with SARS-COV-2 severe pneumonia. *Ann Intensive Care* 10(1):60. <https://doi.org/10.1186/s13613-020-00680-w>
- Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS (2020) Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. *Lancet Respir Med* 8(7):681–686. [https://doi.org/10.1016/S2213-2600\(20\)30243-5](https://doi.org/10.1016/S2213-2600(20)30243-5)
- Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD (2000) Angiotensin-1 protects the adult vasculature against plasma leakage. *Nat Med* 6(4):460–463. <https://doi.org/10.1038/74725>
- Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD (1996) Isolation of angiotensin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. *Cell* 87(7):1161–1169
- Kumpers P, Lukasz A, David S, Horn R, Hafer C, Faulhaber-Walter R, Fliser D, Haller H, Kielstein JT (2008) Excess circulating angiotensin-2 is a strong predictor of mortality in critically ill medical patients. *Crit Care* 12(6):R147. <https://doi.org/10.1186/cc7130>
- Parikh SM, Mammoto T, Schultz A, Yuan HT, Christiani D, Karumanchi SA, Sukhatme VP (2006) Excess circulating angiotensin-2 may contribute to pulmonary vascular leak in sepsis in humans. *PLoS Med* 3(3):e46. <https://doi.org/10.1371/journal.pmed.0030046>
- Higgins SJ, De Ceunynck K, Kellum JA, Chen X, Gu X, Chaudhry SA, Schulman S, Libermann TA, Lu S, Shapiro NI, Christiani DC, Flaumenhaft R, Parikh SM (2018) Tie2 protects the vasculature against thrombus formation in systemic inflammation. *J Clin Invest* 128(4):1471–1484. <https://doi.org/10.1172/JCI97488>
- Smadja DM, Guerin CL, Chocron R, Yatim N, Boussier J, Gendron N, Khider L, Hadjadj J, Goudot G, Debuc B, Juvin P, Hauw-Berlemont C, Augy JL, Peron N, Messas E, Planquette B, Sanchez O, Charbit B, Gaussem P, Duffy D, Terrier B, Mirault T, Diehl JL (2020) Angiotensin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of

- COVID-19 patients. *Angiogenesis*. <https://doi.org/10.1007/s10456-020-09730-0>
28. Kong Y, Han J, Wu X, Zeng H, Liu J, Zhang H (2020) VEGF-D: a novel biomarker for detection of COVID-19 progression. *Crit Care* 24(1):373. <https://doi.org/10.1186/s13054-020-03079-y>
  29. Dupont V, Kanagaratnam L, Goury A, Poitevin G, Bard M, Julien G, Bonnivard M, Champenois V, Noel V, Mourvillier B, Nguyen P (2020) Excess soluble fms-like tyrosine kinase 1 correlates with endothelial dysfunction and organ failure in critically ill COVID-19 patients. *Clin Infect Dis*. <https://doi.org/10.1093/cid/ciaa1007>
  30. van der Flier M, van Leeuwen HJ, van Kessel KP, Kimpen JL, Hoepelman AI, Geelen SP (2005) Plasma vascular endothelial growth factor in severe sepsis. *Shock* 23(1):35–38. <https://doi.org/10.1097/01.shk.0000150728.91155.41>
  31. Sela S, Natanson-Yaron S, Zcharia E, Vlodaysky I, Yagel S, Keshet E (2011) Local retention versus systemic release of soluble VEGF receptor-1 are mediated by heparin-binding and regulated by heparanase. *Circ Res* 108(9):1063–1070. <https://doi.org/10.1161/CIRCRESAHA.110.239665>
  32. Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI (2020) Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. *Lancet Haematol* 7(8):e575–e582. [https://doi.org/10.1016/S2352-3026\(20\)30216-7](https://doi.org/10.1016/S2352-3026(20)30216-7)
  33. Levi M, Scully M, Singer M (2018) The role of ADAMTS-13 in the coagulopathy of sepsis. *J Thromb Haemost* 16(4):646–651. <https://doi.org/10.1111/jth.13953>
  34. Martinelli N, Montagnana M, Pizzolo F, Friso S, Salvagno GL, Forni GL, Gianesi B, Morandi M, Lunardi C, Lippi G, Polati E, Olivieri O, De Franceschi L (2020) A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19. *Thromb Res* 193:170–172. <https://doi.org/10.1016/j.thromres.2020.07.034>
  35. Lukasz A, Hillgruber C, Oberleithner H, Kusche-Vihrog K, Pavenstadt H, Rovas A, Hesse B, Goerge T, Kumpers P (2017) Endothelial glycocalyx breakdown is mediated by angiopoietin-2. *Cardiovasc Res* 113(6):671–680. <https://doi.org/10.1093/cvr/cvx023>
  36. Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, Barthel L, Zemans RL, Bowman JC, Koyanagi DE, Yunt ZX, Smith LP, Cheng SS, Overdier KH, Thompson KR, Geraci MW, Douglas IS, Pearse DB, Tuder RM (2012) The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. *Nat Med* 18(8):1217–1223. <https://doi.org/10.1038/nm.2843>
  37. Nadkarni GN, Lala A, Bagiella E, Chang HL, Moreno P, Pujadas E, Arvind V, Bose S, Charney AW, Chen MD, Cordon-Cardo C, Dunn AS, Farkouh ME, Glicksberg B, Kia A, Kohli-Seth R, Levin MA, Timsina P, Zhao S, Fayad ZA, Fuster V (2020) Anticoagulation, mortality, bleeding and pathology among patients hospitalized with COVID-19: a single health system study. *J Am Coll Cardiol*. <https://doi.org/10.1016/j.jacc.2020.08.041>

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Affiliations

Alexandros Rovas<sup>1</sup> · Irina Osiaevi<sup>1</sup> · Konrad Buscher<sup>1</sup> · Jan Sackarnd<sup>2</sup> · Phil-Robin Tepassee<sup>3</sup> · Manfred Fobker<sup>4</sup> · Joachim Kühn<sup>5</sup> · Stephan Braune<sup>6</sup> · Ulrich Göbel<sup>7</sup> · Gerold Thölking<sup>1,8</sup> · Andreas Gröschel<sup>9</sup> · Hermann Pavenstädt<sup>1</sup> · Hans Vink<sup>10</sup> · Philipp Kumpers<sup>1</sup> 

Alexandros Rovas  
alexandros.rovas@ukmuenster.de

Irina Osiaevi  
irina.osiaevi@ukmuenster.de

Konrad Buscher  
konrad.buscher@ukmuenster.de

Jan Sackarnd  
jan.sackarnd@ukmuenster.de

Phil-Robin Tepassee  
phil-robin.tepassee@ukmuenster.de

Manfred Fobker  
manfred.fobker@ukmuenster.de

Joachim Kühn  
joachim.kuehn@ukmuenster.de

Stephan Braune  
stephan.braune@sfn-muenster.de

Ulrich Göbel  
ulrich.goebel@sfn-muenster.de

Gerold Thölking  
gerold.thoelking@ukmuenster.de

Andreas Gröschel  
a.groeschel@alexianer.de

Hermann Pavenstädt  
hermann.pavenstaedt@ukmuenster.de

Hans Vink  
h.vink@maastrichtuniversity.nl

<sup>1</sup> Department of Medicine D, Division of General Internal and Emergency Medicine, Nephrology, and Rheumatology, University Hospital Münster, Albert-Schweitzer- Campus 1, 48149 Münster, Germany

<sup>2</sup> Department of Cardiology and Angiology, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149 Münster, Germany

<sup>3</sup> Department of Medicine B for Gastroenterology, Hepatology, Endocrinology, Clinical Infectiology, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149 Münster, Germany

<sup>4</sup> Center for Laboratory Medicine, University Hospital Münster, Albert-Schweitzer- Campus 1, 48149 Münster, Germany

<sup>5</sup> Institute of Virology, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149 Münster, Germany

<sup>6</sup> Department of medical internal intensive care and emergency medicine, St. Franziskus-Hospital GmbH, 48145 Münster, Germany

<sup>7</sup> Department of Anaesthesiology and Critical Care, St. Franziskus-Hospital GmbH, 48145 Münster, Germany

<sup>8</sup> Department of Internal Medicine and Nephrology, University Hospital Münster Marienhospital Steinfurt, 48565 Steinfurt, Germany

<sup>9</sup> Department of Pulmonology, Clemenshospital, Münster, Germany

<sup>10</sup> Department of Physiology, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands